Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO BSE: 500660 SECTOR: Pharmaceuticals & Drugs  28k   162   20

1703.65
-53.70 (-3.06%)
NSE: 26 Nov 03:59 PM

Price Summary

Today's High

₹ 1788

Today's Low

₹ 1700

52 Week High

₹ 1824

52 Week Low

₹ 1376

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

28860.86 Cr.

Enterprise Value

27703.21 Cr.

No. of Shares

16.94 Cr.

P/E

58.52

P/B

22

Face Value

₹ 10

Div. Yield

1.77 %

Book Value (TTM)

₹  77.45

CASH

1157.68 Cr.

DEBT

0.02 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  29.11

Sales Growth

-0.96%

ROE

21.3 %

ROCE

32.95%

Profit Growth

224.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glaxosmithkline Pharmaceuticals Ltd.

Piriton Betnovate Augmentin Ceftum Calpol Phexin Betnesol Eltroxin Zinetac Neosporin Cetzine Havrix Varilrix Rotarix Hiberix Cervarix Crocin Eno IODEX Horlicks OSTOCALCIUM Otrivin ActiGrow Choco

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.96%
3 Year3.61%
5 Year2.48%

Profit Growth

1 Year224.91%
3 Year0.53%
5 Year-0.92%

ROE%

1 Year21.3%
3 Year15.66%
5 Year16%

ROCE %

1 Year32.95%
3 Year26.97%
5 Year26.28%

Debt/Equity

0

Price to Cash Flow

48.52

Interest Cover Ratio

156.670895395594

CFO/PAT (5 Yr. Avg.)

1.3934369257721

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 75 0
Jun 2021 75 0
Mar 2021 75 0
Dec 2020 75 0
Sep 2020 75 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.153 Cr.
  • Company has been maintaining healthy ROCE of 26.9712396503776% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 156.670895395594.
  • Company’s PEG ratio is 0.260218667086024.
  • The company has an efficient Cash Conversion Cycle of 14.3354507692455 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.3934369257721.
  • The company has a high promoter holding of 75%.

 Limitations

  • The company has shown a poor profit growth of 0.525650163497682% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.60659431617714% for the Past 3 years.
  • The company is trading at a high PE of 58.52.
  • The company is trading at a high EV/EBITDA of 30.9705.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 879.39 858.42 807.27 773.46 991.53
Total Expenditure 674.37 651.63 638.48 622.77 717.14
Operating Profit 205.02 206.79 168.79 150.69 274.39
Other Income 8.92 13.87 29.61 31.73 15.05
Interest 0.88 0.94 0.63 0.79 0.35
Depreciation 21.96 17.71 17.85 17.71 17.6
Exceptional Items -64.13 10.53 -119 0 0
Profit Before Tax 126.97 212.54 60.92 163.92 271.49
Tax 50.47 55.19 48.18 43.52 68.84
Profit After Tax 76.5 157.35 12.74 120.4 202.65
Adjusted EPS (Rs) 4.52 9.29 0.75 7.11 11.96

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 2902.99 2871.69 3128.53 3224.68 3193.74
Total Expenditure 2483.05 2363.25 2522.05 2566.23 2498.78
Operating Profit 419.93 508.44 606.48 658.45 694.96
Other Income 72.01 53.52 101.48 77.56 110.19
Interest 0.25 0.19 0.55 6.34 3.53
Depreciation 26.35 37.99 48.59 82.68 79.28
Exceptional Items 45.73 17.8 4.89 -324.49 -172.6
Profit Before Tax 511.08 541.58 663.71 322.5 549.74
Tax 174.3 189.6 238.35 212.45 192.17
Net Profit 336.78 351.99 425.36 110.05 357.57
Adjusted EPS (Rs.) 19.88 20.78 25.11 6.5 21.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 84.7 84.7 169.41 169.41 169.41
Total Reserves 1943.51 1995.25 1973.01 1670.63 1348.53
Borrowings 0.99 0.58 0.18 0.02 0
Other N/C liabilities 3638.67 2572.21 2834.88 180.54 178.87
Current liabilities 878.32 2945.16 2800.62 1002.07 1297.32
Total Liabilities 6546.19 7597.9 7778.1 3022.68 2994.12
Assets
Net Block 252.71 322.81 429.99 756.59 384.27
Capital WIP 573.22 922.9 1002.64 120.12 13.21
Intangible WIP 32.25 0 0 0 0
Investments 52.99 49.43 26.17 25.97 25.82
Loans & Advances 3817.84 2785.85 2970.52 356.05 392.45
Other N/C Assets 6.47 4.75 7.84 7.17 7.03
Current Assets 1810.7 3512.17 3340.93 1756.78 2171.33
Total Assets 6546.19 7597.9 7778.1 3022.68 2994.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 465.35 523.79 658.82 646.99 722.33
Adjustment -45.42 -11.15 -30.52 14.2 -25.25
Changes in Assets & Liabilities -29.47 163.69 -7.58 43.59 63.03
Tax Paid -160.86 -201.82 -194.15 -179.55 -146.91
Operating Cash Flow 232.28 474.77 411.18 490.97 594.87
Investing Cash Flow 303.08 -107.01 -154.44 -63.1 408.15
Financing Cash Flow -510.76 -306.63 -358.36 -427.62 -696.14
Net Cash Flow 24.59 61.12 -101.62 0.25 306.87

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 75.00 75.00 75.00 75.00 75.00
glaxo group limited 35.99 35.99 35.99 35.99 35.99
glaxosmithkline pt... 28.10 28.10 28.10 28.10 28.10
eskaylab limited 6.94 6.94 6.94 6.94 6.94
burroughs wellcome... 3.97 3.97 3.97 3.97 3.97
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 25.00 25.00 25.00 25.00 25.00
life insurance cor... - - - 4.78 -
lic of india healt... - 4.78 4.78 - -
qualified institut... - - - 5.33 -
life insurance cor... 5.02 - - - -
lic jeevan plus gr... - - - - 4.70
aditya birla sun l... - - - 3.47 3.42
aditya birla sun l... - - 3.47 - -
aditya birla sun l... 3.46 3.46 - - -
general insurance ... 1.11 1.28 1.42 1.42 1.42
iepf 0.51 0.51 0.51 0.23 0.54
alternative invest... - 0.01 - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ3FY20 14 Aug 2021

Glaxosmithkline Phar Stock Price Analysis and Quick Research Report. Is Glaxosmithkline Phar an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glaxosmithkline Phar and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 594.8654 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glaxosmithkline Phar has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glaxosmithkline Phar , the EPS growth was 224.906090360428 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glaxosmithkline Phar has OPM of 21.7601027360963 % which is a good sign for profitability.
     
  • ROE: Glaxosmithkline Phar have a healthy ROE of 21.2966239022959 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Glaxosmithkline Phar

X